Skip to main content

Market Overview

GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

Share:
GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition.

What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses.

The preclinical data suggests VIR-7831 could potentially block viral entry into healthy cells while also clearing infected cells, the companies said, noting that “the antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop.”

Earlier this month, a Phase 3 trial evaluating VIR-7831 as a monotherapy for the early treatment of COVID-19 showed an 85% reduction in hospitalization or death from those receiving VIR-7831 versus those receiving a placebo.

As a result, the Independent Data Monitoring Committee coordinating the trial recommended a halt in patient enrollment based on the efficacy level.

Related Link: GSK Out-Licenses Two Drug Candidates To Boston Pharmaceuticals

What Happens Next: GlaxoSmithKline and Vir Biotechnology are also in discussions with the European Medicines Agency and other global regulators for similar emergency authorizations in order to make VIR-7831 widely and quickly available.

Separate from this endeavor, GlaxoSmithKline is collaborating with other companies, including Sanofi (NASDAQ: SNY), CureVac (NASDAQ: CVAC) and Medicago Inc. on the development of COVID-19 vaccines.

Related Link: 3 Biotech Stocks That Could Double In 12 Months

Photo by Daniel Roberts / Pixabay.

 

Related Articles (GSK + VIR)

View Comments and Join the Discussion!

Posted-In: Covid-19 MedicagoBiotech News Health Care FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com